Clinical Trial Update: A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 fixed-dose study of 323U66 SR in major depressive disorder has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• 323U66 SR

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2013-05-06